Start here if you're new
what it is
Lipocine tries to turn hard-to-swallow drugs into pills, then make money from one approved testosterone product and several clinical bets.
how it gets paid
Last year Lipocine made $2M in revenue.
why growth slowed
Revenue fell 82.3% last year. The key number is $831K, because one decent quarter still leaves the company at just about $2 million of trailing revenue.
what just happened
Latest quarter revenue hit $831K, but EPS fell to -$1.35, which tells you the pipeline is still eating far more cash than sales can cover.
At a glance
C++ balance sheet — some cracks in the foundation
10/100 earnings predictability — expect surprises
0.0% return on capital — nothing to write home about
$0.00 fy2024 eps est
$11M fy2024 rev est
xvary composite: 36/100 — weak
What they do
Lipocine tries to turn hard-to-swallow drugs into pills, then make money from one approved testosterone product and several clinical bets.
The edge is the Lip'ral delivery platform. Platform → a repeatable drug-delivery tool → so what: you are betting one formulation engine can feed multiple shots on goal with just 16 employees. The catch is simple: one approved product exists today, while the rest of the story sits in trials.
How they make money
$2M
annual revenue · revenue declined -82.3% last year
total revenue
$2M
82.3%
The products that matter
reported revenue line
Product Royalties & Licensing
$2M · 100% of revenue
This is the only reported revenue line on the page, and it came in at $2M. When one bucket is the whole income statement, you are not looking at a diversified business.
current revenue
lead pipeline asset
LPCN 1154
$54M market cap context
In a company worth about $54M, a single asset can dominate the narrative. That is why LPCN 1154 shows up everywhere in the risk discussion even though it contributes $0 to current revenue.
key catalyst
delivery technology platform
oral delivery technology
$11M fy2024 rev est
The platform only matters to shareholders if it turns into dollars. Analysts model $11M for FY2024 revenue, which tells you the market is still underwriting future proof, not current scale.
still needs proof
Key numbers
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: Lipocine loses more than five dollars for every dollar of sales.
$9M
estimate gap
One source modeled about $11 million for fiscal 2024 revenue, while SEC-filed trailing revenue is about $2 million, so your starting assumptions matter more than usual.
$54M
market cap
The whole company is valued at about $54 million, which is small enough for one clinical update to move the stock hard.
5/100
price stability
Price stability → how steady the stock tends to trade → so what: this name behaves more like a biotech lottery ticket than a sleep-at-night holding.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for LPCN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter revenue hit $831K, but EPS fell to -$1.35, which tells you the pipeline is still eating far more cash than sales can cover.
Quarterly revenue jumped 626% vs. prior year, but that came off a tiny base. Revenue growth → more money coming in → so what: it does not matter much yet when operating margin n/a (verify filings).
$831K
revenue
$1.35
eps
$2.0M
ttm revenue
the number that mattered
The key number is $831K, because one decent quarter still leaves the company at just about $2 million of trailing revenue.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is LPCN 1154 disappointing. In a $54M company with $2M in revenue, one failed readout or commercial miss can overwhelm everything else on the page.
med
LPCN 1154 disappoints
This is the single-asset problem stated plainly. If the lead program fails to support the thesis, the stock loses the future before the current business is large enough to defend the present.
Current reported revenue is only $2M, so there is not much operating ballast if sentiment breaks.
med
the $11M revenue estimate proves too optimistic
The market is already looking far beyond the current $2M revenue base. If that forecast gets cut, investors are not just revising a number. They are revising the whole timeline.
That gap — $11M expected versus $2M currently reported — is the part of the story doing the valuation work.
med
funding pressure arrives before operating proof
A C++ balance sheet and $0.00 EPS estimate are not fatal by themselves. They become a problem if progress takes longer than management can finance comfortably.
No dividend, no earnings, and a 0.0% return on capital mean shareholders are relying on future milestones to fund future confidence.
The combined risk picture is simple: nearly all of the valuation rests on future execution while the current business only produces $2M in revenue.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next company update
The next update matters because this story still lives on milestones. Use it to check whether management is adding proof or just extending the wait.
risk
LPCN 1154
This is the main fault line. If the lead asset weakens, the rest of the page does not offer much fundamental padding.
metric
revenue versus the estimate gap
Track whether reported revenue starts closing the distance to the $11M FY2024 estimate. Same story, very different credibility depending on that gap.
trend
balance sheet direction
C++ is manageable for a while. It gets more dangerous if the business stays at $2M in revenue while progress keeps moving into the future.
Analyst rankings
short-term outlook
mixed
target coverage is thin. in human-speak, analysts do not have a clean shared view of what happens next.
risk profile
volatile
price stability is 5 / 100. Translation: expect bigger swings than the average stock, especially around pipeline headlines.
chart momentum
catalyst-driven
This trades more on trial and funding expectations than on smooth technical trends. Welcome to small-cap biotech.
earnings predictability
10/100
Predictability is near the floor. That usually means the business model is still changing shape underneath the estimates.
source: institutional data
Institutional activity
institutional ownership data for LPCN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive